Quarterly ResultApr 9, 2026, 07:46 AM
ImmunityBio Announces Preliminary Unaudited Q1 2026 Financial Results
AI Summary
ImmunityBio, Inc. announced preliminary, unaudited financial results for the fiscal quarter ended March 31, 2026, along with additional company updates. These results are based on preliminary estimates available as of April 9, 2026, and are not a comprehensive statement of the company's operating results or financial position. Investors should note that the actual amounts reported in the upcoming Form 10-Q may differ materially from these preliminary estimates due to standard financial closing procedures and potential final adjustments. The announcement provides an early look at the company's performance, though specific figures were not detailed in the filing.
Key Highlights
- ImmunityBio, Inc. issued a press release on April 9, 2026, announcing preliminary, unaudited financial results for the fiscal quarter ending March 31, 2026.
- The announced results are preliminary estimates based solely upon information available to the company as of the date of the press release.
- The reported amounts do not constitute a comprehensive statement of ImmunityBio's operating results or financial position for the quarter.
- Actual financial results to be reported in the Quarterly Report on Form 10-Q for Q1 2026 are subject to financial closing procedures and final adjustments.
- These preliminary estimates may differ materially from the final results disclosed in the company's consolidated financial statements.
Price Impact
More from IBRX